Actively Recruiting
Evaluation of SPN-817 Compared to Placebo in Adults With Focal Onset Seizures to Assess Efficacy and Safety
Led by Supernus Pharmaceuticals, Inc. · Updated on 2026-10-01
216
Participants Needed
63
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy, safety, and tolerability of SPN-817 as an additional treatment in adults with focal onset seizures who have not responded to at least two anti-seizure medications. This Phase 2, double-blind, randomized, placebo-controlled study involves multiple centers and compares SPN-817 to a placebo in adults aged 18 to 70 years taking 1 to 4 anti-seizure medications and experiencing at least four seizures during a six-week screening period. Participants will be randomly assigned in a 21 ratio to receive either SPN-817 3.0 to 4.0 mg twice daily or a placebo. The study includes a titration period lasting 8 to 10 weeks during which an antiemetic medication, ondansetron, is taken prophylactically before each dose to manage potential side effects. After reaching the target dose, participants enter a maintenance period lasting 14 weeks. Ondansetron may be used as needed during this phase. After completing the maintenance period, participants may join a separate open-label study for continued SPN-817 treatment or undergo a tapering period of up to four weeks, followed by a safety follow-up phone call. Throughout the trial, participants will keep electronic seizure diaries, and the research team will monitor seizure frequency and treatment-emergent adverse events. The main measurement is the percent change in seizure frequency during the maintenance period compared to baseline. Additional evaluations include the proportion of participants with significant seizure reduction and seizure-free intervals. The total study involvement includes the screening, titration, maintenance, tapering, and follow-up periods, with assessments to track safety and treatment effects.
CONDITIONS
Brief Title
RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures
Research Team
S
Supernus Clinical Trials
N
Navid Saeidi, MS
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here